RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Ilya Goldshleger sold 9,000 shares of RxSight stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the completion of the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $1,658,155.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
RxSight Stock Performance
NASDAQ:RXST opened at $49.35 on Friday. The firm’s 50-day moving average is $52.69 and its 200-day moving average is $53.37. RxSight, Inc. has a 52-week low of $20.66 and a 52-week high of $66.54. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -39.17 and a beta of 1.19.
RxSight (NASDAQ:RXST – Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The company had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.33 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The business’s revenue was up 67.6% compared to the same quarter last year. Equities analysts predict that RxSight, Inc. will post -0.75 EPS for the current year.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in RXST. Vanguard Group Inc. increased its holdings in shares of RxSight by 21.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after purchasing an additional 255,150 shares during the period. Arizona State Retirement System bought a new stake in RxSight in the fourth quarter valued at about $261,000. Clarus Group Inc. bought a new stake in RxSight in the fourth quarter valued at about $202,000. New York State Common Retirement Fund increased its stake in RxSight by 25.8% in the fourth quarter. New York State Common Retirement Fund now owns 135,438 shares of the company’s stock valued at $5,461,000 after acquiring an additional 27,758 shares during the period. Finally, Precision Wealth Strategies LLC bought a new stake in RxSight in the fourth quarter valued at about $287,000. Institutional investors own 78.78% of the company’s stock.
RxSight Company Profile
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Recommended Stories
- Five stocks we like better than RxSight
- Airline Stocks – Top Airline Stocks to Buy Now
- Owens-Corning Stock: Good Value or Recession Red Flag?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Datadog Exceeds Q2 Expectations, Solidifies Market Leadership
- How Investors Can Find the Best Cheap Dividend Stocks
- Cybersecurity Stock Surges, Promising Double-Digit Gains
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.